Perindopril Erbumine

New Delhi: A study conducted to test the effectiveness of anti-hypertensive pill combinations in South Asians with uncontrolled hypertension has found three drug combinations effective and safe in reducing ambulatory and office blood pressure. The Centre for Chronic Disease Control in collaboration with the All India Institute of Medical Sciences (AIIMS), and Imperial College, London, undertook a two year long study titled: Treatment Optimisation for Blood Pressure with Single-Pill Combinations in India (TOPSPIN) to test the effectiveness of three double anti-hypertensive pill combinations in South Asian populations. The TOPSPIN Study evaluated three two-drug combinations: Amlodipine + Perindopril; Amlodipine + Indapamide; and Perindopril + Indapamide. It found all three combinations equally effective and safe in reducing ambulatory and office blood pressure and were similarly effective in achieving BP control. Findings suggest that, with all the three combinations the absolute BP reduction at six months was around 14/8 mmHg (Ambulatory BP) and about 30/14 mmHg (Office BP) and the BP control was achieved in approximately 70 per cent of participants to <140/90 mmHg that is 5 times the current BP control rates in India with just a single pill. Prof (Dr) Dorairaj Prabhakaran, Executive Director, CCDC, and one of the Principal Investigators said, “The study demonstrates that once a day single pill combination of two blood pressure lowering drugs can control blood pressure effectively. This is in conformity with several international guidelines, eases the management of hypertension and provides wider choices to doctors. With this evidence, healthcare professionals can be better equipped in recommending any of these three combination therapies in managing hypertension among South Asians.” As per the release, one of the notable outcomes of the study was the lack of significant difference in BP control between the combinations tested, which contrasts with findings from the CREOLE study conducted in Sub-Saharan Africa, where different results were observed. The findings suggested that the combination therapies tested may have different effectiveness by ethnicity.> By Online Bureau ,

WEDNESDAY, Sept. 11, 2024 -- For patients with resistant hypertension , a quadruple single pill is superior to triple therapy, according to a study presented at the European Society of Cardiology Congress, held from Aug. 30 to Sept. 2 in London. Stefano Taddei, from the University of Pisa in Italy, and colleagues conducted a double-blind, randomized trial involving patients with resistant hypertension. Participants completed an eight-week run-in period during which they received the triple combination of perindopril, indapamide, and amlodipine. Those with uncontrolled blood pressure (BP) after eight weeks while adherent to therapy were randomly allocated to continue the same triple therapy or receive a single-pill combination containing perindopril, indapamide, amlodipine, and bisoprolol. A total of 183 patients from 49 centers in 13 countries were included in the trial. The researchers found that the mean office sitting systolic BP was reduced by 20.67 and 11.32 mm Hg in the quadruple single-pill group and in the triple group, respectively, after eight weeks, with the adjusted difference significant in favor of the quadruple single pill. For the main secondary end point of mean 24-hour ambulatory systolic BP, there was a significant difference for the quadruple single pill versus the triple group (−7.53 mm Hg); in addition, there was a significant difference in favor of the quadruple single-pill group in mean office sitting diastolic BP (−6.14 mm Hg). BP control was achieved by 66.3 and 42.7 percent on the quadruple single pill and on triple therapy, respectively. "The availability of a quadruple single-pill combination that includes bisoprolol could help with non-adherence and provide much-needed effective BP control in patients with resistant or difficult-to-treat hypertension," Taddei said in a statement. Several authors disclosed ties to the pharmaceutical and medical device industry, including Servier, which funded the study. Press Release More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.